Physician profile
Robert S Hamilton
NPI 1164431904
$67,236.21
in general payments reported to CMS, 2019-2025
14 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,670 · 2020: $6,334 · 2021: $6,182 · 2022: $5,597 · 2023: $8,546 · 2024: $16K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $22K · Honoraria: $15K · Food and Beverage: $2,615 · Travel and Lodging: $2,163 · Education: $0.01.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $21,500.00 |
| Honoraria | $15,175.00 |
| Food and Beverage | $2,615.04 |
| Travel and Lodging | $2,163.25 |
| Education | $0.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $40,395.34 | 2023-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12,189.18 | 2020-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $5,125.59 | 2022 | |
| Allergan, INC. | $4,661.60 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $2,905.46 | 2019 | |
| Sunovion Pharmaceuticals INC. | $735.99 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $363.90 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $215.74 | 2022-2023 | Aristada, Aristada Initio |
| Corium, LLC | $181.78 | 2022-2024 | Azstarys |
| Abbvie INC. | $125.40 | 2022-2023 | |
| Ironshore Pharmaceuticals INC. | $124.71 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $110.44 | 2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $85.06 | 2019 | |
| Novo Nordisk INC | $16.02 | 2025 | Wegovy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Hamilton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.